Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ, Maher TD, Dean DA, Bailey SH, Marrone G, Benckart DH, et al: Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting
Member Spotlight Jared Before I started taking GLP-1 medication through Ro, I was prediabetic and on my way toward Type 2 diabetes
Investigators value this compound due to its specificity, stability, and consistent behavior in experimental models
Most clinics expect visible changes within two to three months